Safety considerations with gastrointestinally active lipid-lowering drugs

被引:59
作者
Jacobson, Terry A.
Armani, Annemarie
McKenney, James M.
Guyton, John R.
机构
[1] Emory Univ, Off Hlth Promot & Dis Prevent, Fac Off Bldg, Atlanta, GA 30303 USA
[2] Imprint Sci, New York, NY USA
[3] Natl Clin Res Inc, Richmond, VA USA
[4] Duke Univ, Med Ctr, Durham, NC USA
关键词
D O I
10.1016/j.amjcard.2006.11.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gastrointestinally active agents such as cholesterol absorption inhibitors (CAIs) (eg, ezetimibe) and bile acid sequestrants (BAS) (the resins cholestyramine and colestipol, or colesevelam, a nonabsorbable polymer) offer important options for lipid-lowering therapy. Ezetimibe is a novel CAI that inhibits the absorption of dietary and biliary cholesterol without affecting the absorption of triglycerides or fat-soluble vitamins. In clinical trials, there has been no evidence of increased rates of myopathy or rhabdomyolysis associated with ezetimibe, whether in use as monotherapy or in a combination with statin therapy, although there exist case reports of possible ezetimibe-associated myopathy. Ezetimibe alone does not appear to increase liver transaminase levels significantly, but the coadministration of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) with ezetimibe marginally increases this risk. However, reported increases in liver enzymes have not been associated with clinically meaningful symptoms and often return to baseline levels after the discontinuation of therapy or with continued treatment. To date, no cases of liver failure, liver transplantation, or death have been reported. BAS have been used clinically since the 1960s for lowering low-density lipoprotein cholesterol. Because they are not absorbed from the gastrointestinal tract into the blood, these agents do not contact most body organs and are therefore systemically safe. However, case reports and pharmacokinetic data disclose 3 kinds of adverse effects: (1) the decreased absorption of concomitant medications and sometimes of certain vitamins; (2) the physicochemical alteration of intestinal contents leading to constipation and, very rarely, intestinal obstruction; and (3) modest increases in plasma triglyceride levels due to the alteration of hepatic lipid metabolism. The newest BAS, colesevelam, has greater specificity for bile acids compared with the older agents cholestyramine and colestipol, eliminating most drug interactions and reducing the tendency for constipation. Overall, CAIs and BAS have excellent systemic safety profiles when used alone or in combination with other lipid-lowering drugs. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:47C / 55C
页数:9
相关论文
共 55 条
  • [1] Colesevelam hydrochloride: A novel bile acid-binding resin
    Aldridge, MA
    Ito, MK
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) : 898 - 907
  • [2] Prevention and Rehabilitation - Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study
    Ballantyne, CM
    Abate, N
    Yuan, Z
    King, TR
    Palmisano, J
    [J]. AMERICAN HEART JOURNAL, 2005, 149 (03) : 464 - 473
  • [3] Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
    Ballantyne, CM
    Blazing, MA
    King, TR
    Brady, WE
    Palmisano, J
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (12) : 1487 - 1494
  • [4] Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial
    Ballantyne, CM
    Houri, J
    Notarbartolo, A
    Melani, L
    Lipka, LJ
    Suresh, R
    Sun, S
    LeBeaut, AP
    Sager, PT
    Veltri, EP
    [J]. CIRCULATION, 2003, 107 (19) : 2409 - 2415
  • [5] Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
    Bays, HE
    Davidson, M
    Jones, MR
    Abby, SL
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (08) : 1198 - 1205
  • [6] A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia
    Bays, HE
    Ose, L
    Fraser, N
    Tribble, DL
    Quinto, K
    Reyes, R
    Johnson-Levonas, AO
    Sapre, A
    Donahue, SR
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (11) : 1758 - 1773
  • [7] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, C
    DOWNTON, M
    FRANKLIN, FA
    GOULD, AL
    HESNEY, M
    HIGGINS, J
    HURLEY, DP
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) : 43 - 49
  • [8] *BRIST MYERS SQUIB, QUESTR CHOL ADV CONS
  • [9] Striated muscle safety of ezetimibe/simvastatin (Vytorin)
    Davidson, MH
    Maccubbin, D
    Stepanavage, M
    Strony, J
    Musliner, T
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (02) : 223 - 228
  • [10] Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
    Davidson, MH
    Ballantyne, CM
    Kerzner, B
    Melani, L
    Sager, PT
    Lipka, L
    Strony, J
    Suresh, R
    Veltri, E
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (08) : 746 - 755